Clinical trials: Depressive Disorder, Major
Depressive Disorder, Major
Switching to Duloxetine in Patients With Depression
The purpose of this study is to help answer the following research question: Whether switching to duloxetine improves depressed mood when current treatment did not work well for patients with depression.
- Trial name
- ARDENT (NCT00696774)
- Testing
- Duloxetine
- Where
- 2 sites in South Korea
- Volunteers
- 242 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Alcohol Abuse
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will…
- Conditions
- Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
- Trial name
- NCT00452543
- Testing
- acamprosate, escitalopram, Medical management
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission
KAP for Depression in Abstinent Opioid Users
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused…
- Conditions
- Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
- Trial name
- KReDO (NCT05193318)
- Testing
- Ketamine-assisted psychotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder…
- Trial name
- NCT00985725
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 33 sites in United States
- Volunteers
- 143 people
- Sponsor
- Shire
Depression
Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse
This study will compare the effectiveness of fluoxetine alone with the effectiveness of fluoxetine with cognitive behavioral therapy in increasing recovery and preventing relapse in youth with major depressive disorder.
- Trial name
- NCT00612313
- Testing
- Fluoxetine, Relapse prevention cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.
- Trial name
- NCT00529789
- Testing
- duloxetine
- Where
- 22 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Virtual Reality Job Interview Training in Severe Mental Illness
This is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (VR-JIT). Northwestern University is partnering with Thresholds Inc.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT03049813
- Testing
- Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Michigan
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Depression
Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or…
- Trial name
- NCT00183729
- Testing
- Memantine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Eric Lenze
Major Depressive Disorder
Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who are undergoing treatment with, but have…
- Trial name
- NCT01148979
- Testing
- Lisdexamfetamine Dimesylate (Vyvanse)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mclean Hospital
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms
The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than…
- Trial name
- NCT01000805
- Testing
- Duloxetine
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 528 people
- Sponsor
- Eli Lilly and Company
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorder
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
- Trial name
- NCT00596622
- Testing
- Lithium
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Indiana University
Major Depressive Disorder
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major depressive disorder (MDD).The primary…
- Trial name
- NCT04244253
- Testing
- OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily
- Where
- Japan
- Volunteers
- 273 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder, Bipolar Depression
Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Mixed states in bipolar disorder have long been recognized. Over a century ago, it was argued that mixed states were the most common episodes in manic-depressive illness.
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- NCT00490542
- Testing
- ziprasidone (Geodon)
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Tufts Medical Center
Major Depressive Disorder
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
The primary purpose of this study is to compare the long-term efficacy and safety of desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive Disorder, using a randomized withdrawal design.
- Trial name
- NCT00887224
- Testing
- Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg
- Where
- 90 sites in United States, Canada and 12 more
- Volunteers
- 874 people
- Sponsor
- Pfizer
Psychotic Disorders, Depressive Disorder, Major
Treatment of Schizoaffective Disorder Using Mifepristone
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
- Conditions
- Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
- Trial name
- NCT00725270
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Severe Asthma, Moderate or Severe Major Depressive Disorder
Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD).
- Trial name
- NCT00621946
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center